Nyhetsarkiv

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B – Data Presented at EAHAD 2022

4 Februari 2022 16:36

Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy. Following a single administration of etranacogene dezaparvovec, participants maintained stable Factor IX (FIX) activity through 18 months.

EMA Grants Accelerated Assessment for CSL Behring’s Haemophilia B Gene Therapy

15 December 2021 15:17

CSL Behring today announced that the European Medicines Agency has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application (MAA). Etranacogene dezaparvovec is an investigational gene therapy for people with haemophilia B, a life-threatening bleeding disorder, and is currently being studied in the Phase 3 HOPE-B clinical trial.

Dr Vuokko Nummi at Helsinki University Hospital receives the CSL Behring Nordic von Willebrand Scholarship

30 November 2021 11:00

The CSL Behring Nordic von Willebrand Scholarship is awarded every two years. Dr Vuokko Nummi receives the 2020 scholarship for research on characterization of microcirculation and associations to angiodysplasia in von Willebrand disease.

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

6 Maj 2021 16:01

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding. uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Nytt avsnitt av "Blödigt värre" – Okunskap och fördomar

11 November 2020 10:23

​Vi pratar med tjugotreåriga Sara som lever med den ovanliga blödardiagnosen ITP (immunologisk trombocytopeni) som drabbar cirka 3 av 100 000 personer varje år. Sara berättar om den okunskap hon stött på i livet och hur den påverkat henne.

Podcasten "Blödigt värre" firar 20 avsnitt

8 Oktober 2020 10:27

Under åren har det hunnit bli 20 olika avsnitt där vi lyfter frågor, sprider kunskap och sticker hål på en del fördomar om blödarsjuka. Medverkar gör unga och gamla med blödarsjuka, föräldrar, läkare och forskare för att samtala och söka svar.

Nytt avsnitt av "Blödigt värre" – Kan träning lindra smärta i lederna?

15 September 2020 15:26

Studier har visat att 60-80 % av de som lever med blödarsjuka lider av daglig smärta och att bara 40 % är nöjda med sin smärtbehandling. Vi pratar med Eva Zetterberg från Koagulationsmottagningen i Skåne om ledsmärta och olika typer av smärtlindring.

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

24 Juni 2020 13:14

Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose. CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B.

CSL Behring to Acquire Biotech Company Vitaeris

8 Juni 2020 15:19

Builds on CSL Behring’s promise and commitment to the transplant community. Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio.

Nytt avsnitt av ”Blödigt värre” – En podcast om livet med blödarsjuka

5 Maj 2020 12:51

Avsnitt 19 – Von Willebrand och ny forskning

CSL Behring Announces Results from Three Analyses of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)

21 April 2020 13:32

Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method.

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

6 April 2020 15:09

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.